| Keywords: |
clinical trial; doxorubicin; cancer growth; antineoplastic agents; paclitaxel; follow up; gene overexpression; breast cancer; gene amplification; proportional hazards models; prevalence; epidermal growth factor receptor 2; cyclophosphamide; breast neoplasms; prediction; risk assessment; central nervous system neoplasms; risk; survival time; antibodies, monoclonal; fluorescence in situ hybridization; proportional hazards model; drug therapy, combination; algorithm; randomized controlled trials; drug response; brain metastasis; short survey; trastuzumab; navelbine; double-blind method; genes, erbb-2; drug exposure; her2; cns; central nervous system metastasis; multicenter studies; clinical trials, phase ii; clinical trials, phase iii
|
